

Special Issue

Recent Advancements in Malignant Pleural Mesothelioma: Diagnosis, Treatment, and Molecular Mechanisms

Message from the Guest Editor

Malignant pleural mesothelioma (MPM) is a dismal and rare disease caused by asbestos exposure. Since asbestos use peaked around 1980 and the latency time to develop MPM is around 20 to 50 years, the number of deaths from MPM in Europe is expected to peak in 2020–2025. The optimal treatment for mesothelioma remains under debate; moreover, there is no international agreement on the role of surgery with curative intent. **FUTURE:** We need to address some open questions:

- What is the role of neoadjuvant treatment?
- Does the immunotherapy revolutionize the approach to MPM as with what happened to NSCLC?
- Which is the best timing for surgery in multimodal treatment?
- Can Artificial Intelligence predict the outcomes of MPM patients?

The aim of this Special Issue is debating and answering the most important controversies about this cruel disease.

Guest Editor

Dr. Sara Ricciardi

Unit of Thoracic Surgery, Azienda Ospedaliera San Camillo Forlanini, Carlo Forlanini Hospital, Circonvallazione Gianicolense 87, 00152 Rome, Italy

Deadline for manuscript submissions

closed (31 March 2025)



**Current
Oncology**

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



mdpi.com/si/172281

Current Oncology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
currentoncology@mdpi.com

[mdpi.com/journal/
currentoncology](https://mdpi.com/journal/currentoncology)





Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



[mdpi.com/journal/
currenocol](https://mdpi.com/journal/currenocol)



About the Journal

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

Journal Rank:

JCR - Q2 (Oncology)